niacinamide has been researched along with Angiogenesis, Pathologic in 206 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the sonographic changes observed in hepatocellular carcinoma (HCC) post antiangiogenic treatment with sorafenib." | 9.16 | Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. ( Chatzimichail, K; Gkoutzios, P; Kalokairinou, M; Karagiannis, E; Kiltenis, M; Kornezos, I; Malagari, K; Moschouris, H; Papadaki, MG; Stamatiou, K, 2012) |
| "Sorafenib plus metronomic tegafur/uracil therapy can induce tumor stabilization in advanced hepatocellular carcinoma (HCC) patients." | 9.15 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW, 2011) |
| "Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma." | 8.88 | Sorafenib for treatment of hepatocellular carcinoma: a systematic review. ( Spechler, SJ; Wang, DH; Xie, B, 2012) |
| "To investigate the effectiveness of intravoxel incoherent motion (IVIM) in the assessment of the therapeutic efficacy of sorafenib in an orthotopic hepatocellular carcinoma (HCC) xenograft model." | 7.85 | Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model. ( Fu, CX; Gao, DM; Han, ZH; Lin, J; Liu, H; Lu, F; Lv, P; Yang, SH, 2017) |
| "The anti-angiogenic Sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC)." | 7.83 | Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. ( Bar-Zion, A; Butz, H; Daley, F; Foster, FS; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S; Reynolds, AR; Vermeulen, PB; Yin, M; Yousef, GM, 2016) |
| " This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking." | 7.83 | Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. ( Kerbel, RS; Kuczynski, EA, 2016) |
| "The aim of this study was to assess the early response to sorafenib using ultrasound molecular imaging in a murine model of hepatocellular carcinoma (HCC)." | 7.81 | Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. ( Baron Toaldo, M; Bolondi, L; Cipone, M; Croci, L; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L, 2015) |
| "Sorafenib is a strong multikinase inhibitor targeting 2 different pathways of endometriosis pathogenesis: RAF kinase and vascular endothelial growth factor receptor (VEGFR)." | 7.81 | Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. ( Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P, 2015) |
| "Our previous studies have demonstrated that sorafenib can promote the dissemination of hepatocellular carcinoma (HCC) through downregulation of HTATIP2, a suppressor of tumor growth and metastasis that is associated with inhibition of angiogenesis." | 7.80 | The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. ( Liu, C; Liu, L; Long, J; Ni, QX; Sun, HC; Tang, ZY; Wang, WQ; Wu, CT; Xu, HX; Xu, J; Yu, XJ; Zhang, W; Zhu, XD, 2014) |
| "Sorafenib is the approved systemic drug of choice for advanced hepatocellular carcinoma (HCC), but has demonstrated limited benefits because of drug resistance." | 7.80 | 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. ( Dong, X; Jiang, X; Li, G; Li, J; Ma, L; Ni, S; Qiao, H; Sun, X; Zhao, D; Zhu, H, 2014) |
| "The multikinase inhibitor sorafenib displays antitumor activity in preclinical models of osteosarcoma." | 7.79 | The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. ( Aglietta, M; Alberghini, M; Basiricò, M; Bruno, S; Capozzi, F; D'Ambrosio, L; Dell'Aglio, C; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Marchiò, S; Picci, P; Pignochino, Y; Sangiolo, D; Soster, M; Torchiaro, E, 2013) |
| "This prospective pilot study investigated the feasibility of perfusion computed tomography parameters as surrogate markers of angiogenesis and early response following sorafenib administration in patients with advanced hepatocellular carcinoma." | 7.79 | Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study. ( Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bresci, G; Faggioni, L; Ginanni, B; Romano, A; Sacco, R, 2013) |
| "The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines." | 7.79 | Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. ( Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E, 2013) |
| "Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular carcinoma (HCC)." | 7.79 | Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. ( Aziz, K; Cades, JA; Chettiar, ST; Cosgrove, D; Gajula, RP; Gandhi, N; Geschwind, JF; Hales, RK; Herman, JM; Kumar, R; Maitra, A; Menon, S; Pawlik, TM; Taparra, K; Torbenson, MS; Tran, PT; Velarde, E; Wild, AT; Williams, RD; Wong, J; Zeng, J, 2013) |
| "Sorafenib has recently been shown to reduce tumour growth in hepatoblastoma (HB) xenografts." | 7.79 | Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts. ( Armeanu-Ebinger, S; Dewerth, A; Eicher, C; Ellerkamp, V; Fuchs, J; Hildenbrand, S; Thomale, J; Warmann, SW, 2013) |
| "Mice with subcutaneous neuroblastoma xenografts or orthotopic adrenal tumors were treated with sorafenib, and tumor growth rates were measured." | 7.78 | Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. ( Chlenski, A; Cohn, SL; Guerrero, LJ; Kakodkar, NC; Maitland, ML; Peddinti, RR; Salwen, HR; Tian, Y; Yang, Q, 2012) |
| "The multikinase inhibitor sorafenib is the first oral agent to show activity against human hepatocellular carcinoma (HCC)." | 7.78 | The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. ( Gao, H; Hu, S; Jiang, H; Kong, J; Li, Z; Shi, B; Yang, Y; Yao, M; Zhang, P, 2012) |
| " We previously showed that the multikinase inhibitor sorafenib activated GSK-3β and that this activation attenuated the cytotoxic effects of the drug in various BRAF-mutant melanoma cell lines." | 7.77 | Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. ( Liu, Q; Mier, JW; Panka, DJ, 2011) |
| "The multi-targeted tyrosine kinase inhibitor sorafenib was the first agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. ( Galle, PR; Gamstätter, T; Niederle, IM; Schadmand-Fischer, S; Schuchmann, M; Spies, PR; Weinmann, A; Wörns, MA, 2011) |
| "To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade prostate intraepithelial neoplasia (HGPIN) into adenocarcinoma (ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic adenocarcinoma mouse prostate (TRAMP) mice." | 7.76 | Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. ( Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F, 2010) |
| "Sorafenib (60 mg/kg) was administered orally to NOD." | 5.42 | Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma. ( Armeanu-Ebinger, S; Dewerth, A; Fuchs, J; Nagel, C; Warmann, SW, 2015) |
| "Treatment with perifosine for 5 weeks, alone and in combination with sorafenib, strongly inhibited tumor growth and increased survival." | 5.42 | Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. ( Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW, 2015) |
| "Treatment with sorafenib led to decreased ERK phosphorylation, reduced cell viability and induction of apoptosis in HepT1 and HUH6 cells." | 5.38 | Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice. ( Armeanu-Ebinger, S; Dewerth, A; Eicher, C; Fuchs, J; Kirchner, B; Warmann, SW, 2012) |
| "The Morris Hepatoma (MH) and HepG2 cells were treated in vitro with sorafenib (1-10 μM) and erlotinib (1-5 μM) and evaluated for tumor cell viability, apoptosis, and target regulation." | 5.38 | Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. ( Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W, 2012) |
| "Patients receiving surgical treatment of endometriosis (n = 4) and control patients without endometriosis (n = 2) undergoing surgery for benign gynecologic diseases." | 5.38 | Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. ( Bussolati, B; Cassoni, P; Marchino, GL; Moggio, A; Pittatore, G; Revelli, A, 2012) |
| "Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a standard of care in advanced HCC." | 5.37 | Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. ( Choo, SP; Chow, PK; Chung, AY; Huynh, H; Ong, R; Soo, KC; Tai, WM; Toh, HC, 2011) |
| " This study was to investigate the effect of rapamycin, alone and in combination with sorafenib, on HCC in vivo." | 5.35 | Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. ( Fan, J; Huang, XW; Qiu, SJ; Tang, ZY; Wang, Z; Yu, Y; Zhou, J, 2008) |
| "Sorafenib is able to inhibit their signal transduction, both in vitro and in vivo, displaying anti-tumoural activity, anti-angiogenic effects, and reducing metastatic colony formation in lungs." | 5.35 | Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. ( Aglietta, M; Alberghini, M; Bottos, A; Bruno, S; Bussolino, F; Camussi, G; Cavalloni, G; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Migliardi, G; Motta, M; Picci, P; Pignochino, Y; Tapparo, M; Torchio, B, 2009) |
| " In the PLC/PRF/5 xenograft model, sorafenib tosylate dosed at 10 mg/kg inhibited tumor growth by 49%." | 5.33 | Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. ( Cao, Y; Carter, C; Chen, C; Liu, L; Lynch, M; McNabola, A; Wilhelm, S; Wilkie, D; Zhang, X, 2006) |
| "To compare the regulation of serum angiogenic factors in patients with unresectable early hepatocellular carcinoma (HCC) treated with yttrium-90 ((90)Y) radioembolization alone vs with sorafenib." | 5.22 | Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. ( Andreoli, JM; Baker, T; Gabr, A; Hickey, R; Kallini, JR; Kircher, S; Kulik, L; Lewandowski, RJ; Salem, R, 2016) |
| "To evaluate the sonographic changes observed in hepatocellular carcinoma (HCC) post antiangiogenic treatment with sorafenib." | 5.16 | Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. ( Chatzimichail, K; Gkoutzios, P; Kalokairinou, M; Karagiannis, E; Kiltenis, M; Kornezos, I; Malagari, K; Moschouris, H; Papadaki, MG; Stamatiou, K, 2012) |
| "Sorafenib plus metronomic tegafur/uracil therapy can induce tumor stabilization in advanced hepatocellular carcinoma (HCC) patients." | 5.15 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW, 2011) |
| "Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 4.91 | Novel drugs in clinical development for hepatocellular carcinoma. ( Trojan, J; Waidmann, O, 2015) |
| "Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma." | 4.88 | Sorafenib for treatment of hepatocellular carcinoma: a systematic review. ( Spechler, SJ; Wang, DH; Xie, B, 2012) |
| "Sorafenib, a multikinase inhibitor targeting vascular endothelial growth factor (VEGF)-mediated angiogenesis, is the first drug found to prolong survival of patients with advanced hepatocellular carcinoma (HCC)." | 4.86 | Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. ( Cheng, AL; Hsu, C; Shen, YC, 2010) |
| " Sorafenib is a multi-kinase inhibitor that targets rapidly accelerated fibrosarcoma (RAF), vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-β (PDGFR-β), and KIT." | 4.12 | Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma. ( Maeda, S; Momoi, Y; Yokota, S; Yonezawa, T, 2022) |
| "To investigate the effectiveness of intravoxel incoherent motion (IVIM) in the assessment of the therapeutic efficacy of sorafenib in an orthotopic hepatocellular carcinoma (HCC) xenograft model." | 3.85 | Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model. ( Fu, CX; Gao, DM; Han, ZH; Lin, J; Liu, H; Lu, F; Lv, P; Yang, SH, 2017) |
| "Sorafenib, sunitinib, and axitinib were administered by oral gavage in a murine model of dextran sodium sulfate (DSS) colitis." | 3.83 | Murine colitis treated with multitargeted tyrosine kinase inhibitors. ( Crawford, K; Dusing, M; Frischer, JS; Knod, JL, 2016) |
| "The anti-angiogenic Sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC)." | 3.83 | Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. ( Bar-Zion, A; Butz, H; Daley, F; Foster, FS; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S; Reynolds, AR; Vermeulen, PB; Yin, M; Yousef, GM, 2016) |
| " This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking." | 3.83 | Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. ( Kerbel, RS; Kuczynski, EA, 2016) |
| "The aim of this study was to assess the early response to sorafenib using ultrasound molecular imaging in a murine model of hepatocellular carcinoma (HCC)." | 3.81 | Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. ( Baron Toaldo, M; Bolondi, L; Cipone, M; Croci, L; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L, 2015) |
| "Sorafenib is a strong multikinase inhibitor targeting 2 different pathways of endometriosis pathogenesis: RAF kinase and vascular endothelial growth factor receptor (VEGFR)." | 3.81 | Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. ( Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P, 2015) |
| "Our previous studies have demonstrated that sorafenib can promote the dissemination of hepatocellular carcinoma (HCC) through downregulation of HTATIP2, a suppressor of tumor growth and metastasis that is associated with inhibition of angiogenesis." | 3.80 | The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. ( Liu, C; Liu, L; Long, J; Ni, QX; Sun, HC; Tang, ZY; Wang, WQ; Wu, CT; Xu, HX; Xu, J; Yu, XJ; Zhang, W; Zhu, XD, 2014) |
| "Sorafenib is the approved systemic drug of choice for advanced hepatocellular carcinoma (HCC), but has demonstrated limited benefits because of drug resistance." | 3.80 | 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. ( Dong, X; Jiang, X; Li, G; Li, J; Ma, L; Ni, S; Qiao, H; Sun, X; Zhao, D; Zhu, H, 2014) |
| "The multikinase inhibitor sorafenib displays antitumor activity in preclinical models of osteosarcoma." | 3.79 | The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. ( Aglietta, M; Alberghini, M; Basiricò, M; Bruno, S; Capozzi, F; D'Ambrosio, L; Dell'Aglio, C; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Marchiò, S; Picci, P; Pignochino, Y; Sangiolo, D; Soster, M; Torchiaro, E, 2013) |
| "This prospective pilot study investigated the feasibility of perfusion computed tomography parameters as surrogate markers of angiogenesis and early response following sorafenib administration in patients with advanced hepatocellular carcinoma." | 3.79 | Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study. ( Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bresci, G; Faggioni, L; Ginanni, B; Romano, A; Sacco, R, 2013) |
| "Currently, only one drug, sorafenib, is FDA approved for the treatment of advanced hepatocellular carcinoma (HCC), achieving modest objective response rates while still conferring an overall survival benefit." | 3.79 | The evolving landscape of therapeutic drug development for hepatocellular carcinoma. ( Chong, DQ; Choo, SP; Tan, IB; Toh, HC, 2013) |
| "The anti-lymphoma activity and mechanism(s) of action of the multikinase inhibitor sorafenib were investigated using a panel of lymphoma cell lines, including SU-DHL-4V, Granta-519, HD-MyZ, and KMS-11 cell lines." | 3.79 | Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. ( Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E, 2013) |
| "Antiangiogenic therapy, specially sorafenib, has become the standard of care for patients with advanced hepatocellular carcinoma (HCC), however, the improvement in survival time is not satisfactory." | 3.79 | Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models. ( Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY, 2013) |
| "Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular carcinoma (HCC)." | 3.79 | Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. ( Aziz, K; Cades, JA; Chettiar, ST; Cosgrove, D; Gajula, RP; Gandhi, N; Geschwind, JF; Hales, RK; Herman, JM; Kumar, R; Maitra, A; Menon, S; Pawlik, TM; Taparra, K; Torbenson, MS; Tran, PT; Velarde, E; Wild, AT; Williams, RD; Wong, J; Zeng, J, 2013) |
| "We previously reported that expressions of the pro-angiogenic cytokines angiopoietin-2 (Ang-2), follistatin, granulocyte colony-stimulating factor, hepatocyte growth factor, leptin, platelet-derived growth factor-BB, platelet endothelial cell adhesion molecule-1, and vascular endothelial growth factor were associated with the response to sorafenib in patients with advanced hepatocellular carcinoma (HCC)." | 3.79 | Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. ( Hagihara, H; Honda, M; Ikeda, F; Iwadou, S; Kaneko, S; Kariyama, K; Kobayashi, Y; Kuwaki, K; Miyahara, K; Miyake, Y; Morimoto, Y; Nakamura, S; Nouso, K; Obi, S; Onishi, H; Sato, S; Sato, T; Shiraha, H; Takabatake, H; Takaguchi, K; Takaki, A; Takeuchi, Y; Takuma, Y; Yamamoto, K, 2013) |
| "Sorafenib has recently been shown to reduce tumour growth in hepatoblastoma (HB) xenografts." | 3.79 | Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts. ( Armeanu-Ebinger, S; Dewerth, A; Eicher, C; Ellerkamp, V; Fuchs, J; Hildenbrand, S; Thomale, J; Warmann, SW, 2013) |
| "Mice with subcutaneous neuroblastoma xenografts or orthotopic adrenal tumors were treated with sorafenib, and tumor growth rates were measured." | 3.78 | Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. ( Chlenski, A; Cohn, SL; Guerrero, LJ; Kakodkar, NC; Maitland, ML; Peddinti, RR; Salwen, HR; Tian, Y; Yang, Q, 2012) |
| "The multikinase inhibitor sorafenib is the first oral agent to show activity against human hepatocellular carcinoma (HCC)." | 3.78 | The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. ( Gao, H; Hu, S; Jiang, H; Kong, J; Li, Z; Shi, B; Yang, Y; Yao, M; Zhang, P, 2012) |
| "Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced hepatocellular carcinoma (HCC)." | 3.78 | Molecular mechanisms of sorafenib action in liver cancer cells. ( Azzolina, A; Bachvarov, D; Cervello, M; Cusimano, A; Lampiasi, N; McCubrey, JA; Montalto, G, 2012) |
| " In the sorafenib era, other antiangiogenic targeted drugs, such as monoclonal antibodies and a new generation of tyrosine kinase inhibitors, have been shown in phase II trials to be safe and effective in the treatment of advanced hepatocellular carcinoma." | 3.78 | Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). ( Amigo, G; Antón, A; Esquerdo, G; García-Otín, AL; Lanzuela, M; Martín-Duque, P; Pazo-Cid, RA; Pérez-Gracia, JL; Trufero, JM, 2012) |
| " We previously showed that the multikinase inhibitor sorafenib activated GSK-3β and that this activation attenuated the cytotoxic effects of the drug in various BRAF-mutant melanoma cell lines." | 3.77 | Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. ( Liu, Q; Mier, JW; Panka, DJ, 2011) |
| "The multi-targeted tyrosine kinase inhibitor sorafenib was the first agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. ( Galle, PR; Gamstätter, T; Niederle, IM; Schadmand-Fischer, S; Schuchmann, M; Spies, PR; Weinmann, A; Wörns, MA, 2011) |
| "To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade prostate intraepithelial neoplasia (HGPIN) into adenocarcinoma (ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic adenocarcinoma mouse prostate (TRAMP) mice." | 3.76 | Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. ( Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F, 2010) |
| "Migration of HUVEC cells, the ability of HUVEC cells to form tubes, and proliferative capacity of a human ocular melanoma cell line were tested in the presence of lenalidomide and sorafenib alone and in combination." | 3.74 | Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. ( Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI, 2007) |
| "Sorafenib 400 mg was administered orally twice daily continuously." | 2.73 | A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. ( Chi, KN; Czaykowski, P; Ellard, SL; Gauthier, I; Hansen, C; Hotte, SJ; Moore, M; Ruether, JD; Schell, AJ; Seymour, L; Taylor, S; Walsh, W, 2008) |
| "Sorafenib is a novel RAF and VEGF receptor tyrosine kinase inhibitor." | 2.73 | Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. ( Flaherty, KT; Gallagher, ML; Heitjan, DF; O'Dwyer, PJ; Rosen, MA; Schnall, MD; Schwartz, B, 2008) |
| " On the other hand, the optimal combination and dosage of these drugs, selection of the apropriate biomarker and better understanding of the conflicting role of PDGFR and FGFR signaling in angiogenesis remain future challenges." | 2.48 | [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors]. ( Döme, B; Török, S, 2012) |
| "Sorafenib has shown anti-tumor activity in NSCLC." | 2.48 | Sorafenib in non-small cell lung cancer. ( Gold, KA; Kim, E; Zhang, J, 2012) |
| "Hepatocellular carcinoma is the leading cause of death in cirrhosis." | 2.46 | Review article: the management of hepatocellular carcinoma. ( Cabrera, R; Nelson, DR, 2010) |
| "Research on angiogenesis in renal carcinoma has brought important advances to understand tumor biology and to allow us development of new antiangiogenic drugs." | 2.46 | [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab]. ( Ayllon, J; Barrascout, E; Cuenod, CA; Elaidi, R; Medioni, J; Mejean, A; Oudard, S; Scotte, F; Tartour, E, 2010) |
| "Treatment of hepatocellular carcinoma has dramatically changed in the last years." | 2.45 | New drugs for the treatment of hepatocellular carcinoma. ( Boucher, E; Bruix, J; Forner, A; Reig, M, 2009) |
| "In most cases, death from bladder cancer results from metastatic disease." | 2.45 | Targeting angiogenesis in bladder cancer. ( Elfiky, AA; Rosenberg, JE, 2009) |
| "Future potential uses of bevacizumab in cancer therapy will be discussed." | 2.45 | The role of antiangiogenesis therapy: bevacizumab and beyond. ( Cortés-Funes, H, 2009) |
| "Sorafenib is a small molecule that blocks cancer cell proliferation by targeting the intracellular signaling pathway at the level of Raf-1 and B-Raf serine-threonine kinases, and exerts an anti-angiogenic effect by targeting the vascular endothelial growth factor receptor-1, 2 and 3, and platelet-derived growth factor receptor-beta tyrosine kinases." | 2.45 | Molecular targeting for treatment of advanced hepatocellular carcinoma. ( Song, IH, 2009) |
| "Renal cell carcinoma is a highly vascular tumor associated with expression of vascular endothelial growth factor (VEGF)." | 2.44 | Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. ( Rini, BI, 2007) |
| "Sporadic renal cell carcinomas are characterized by EGFR (HER-1) and EGFR-2 (HER-2) expression, however, signal transduction inhibitors of this pathway were clinically ineffective." | 2.44 | [Effect of angiogenesis inhibitors on renal cell carcinoma]. ( Bodrogi, I, 2007) |
| "Angiogenesis does not initiate malignancy but promotes tumor progression and metastasis." | 2.44 | [Oral drugs inhibiting the VEGF pathway]. ( Armand, JP; Mir, O; Ropert, S, 2007) |
| "Sorafenib (BAY43-9006) was found to inhibit Raf1, but also VEGFR2 and 3, Flt3, PDGFR-a and b and c-kit, has been tested in a phase III study against placebo after one prior systemic therapy." | 2.44 | [Angiogenesis and renal cell carcinoma]. ( Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L, 2007) |
| "Lung cancer is the most common cause of cancer death worldwide, with most patients dying with metastatic disease." | 2.43 | Angiogenesis and lung cancer: prognostic and therapeutic implications. ( Herbst, RS; Onn, A; Sandler, A, 2005) |
| "Sorafenib is a small molecule inhibitor of several kinases involved in tumour proliferation and tumour angiogenesis including Raf, VEGFR and platelet derived growth factor receptor." | 2.43 | Sorafenib. ( Rini, BI, 2006) |
| "The angiogenic phenotype of renal cell carcinoma results from vascular endothelial growth factor pathway activation." | 2.43 | Molecularly targeted therapy in renal cell carcinoma: where do we go from here? ( Rini, BI, 2006) |
| "Prognostic biomarkers for patients with clear cell renal cell carcinoma (ccRCC), particularly those receiving therapy targeting angiogenesis, are not well established." | 1.48 | Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis. ( Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W, 2018) |
| "Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors." | 1.43 | (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. ( Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T, 2016) |
| "In the present study, we investigated the effects of motesanib (AMG 706), a multikinase inhibitor alone and in combination with DuP-697, an irreversible selective inhibitor of COX-2, on cell proliferation, angiogenesis, and apoptosis induction in a human colorectal cancer cell line (HT29)." | 1.43 | Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells. ( Altun, A; Ataseven, H; Kaya, TT; Koyluoglu, G; Turgut, NH, 2016) |
| "Insufficient thermal ablation promotes residual tumor progression." | 1.43 | Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model. ( Cai, H; Kong, WT; Tang, Y; Wang, WP; Zhang, XL, 2016) |
| "Sorafenib (60 mg/kg) was administered orally to NOD." | 1.42 | Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma. ( Armeanu-Ebinger, S; Dewerth, A; Fuchs, J; Nagel, C; Warmann, SW, 2015) |
| "Treatment with perifosine for 5 weeks, alone and in combination with sorafenib, strongly inhibited tumor growth and increased survival." | 1.42 | Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. ( Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW, 2015) |
| "Sorafenib is a first multi-kinase inhibitor and one of the most widely used small-molecule oral-targeted drugs." | 1.42 | 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases. ( Guo, XL; Li, WB; Lu, YY; Wang, JJ; Zhang, XK, 2015) |
| "Chemotherapy for collecting duct carcinoma (CDC) has demonstrated only limited efficacy in the advanced setting." | 1.40 | Treatment of collecting duct carcinoma: current status and future perspectives. ( Colecchia, M; De Braud, F; Garanzini, E; Grassi, P; Iacovelli, R; Procopio, G; Testa, I; Torelli, T; Verzoni, E, 2014) |
| "Metastatic melanoma is associated with a splicing switch to pro-angiogenic VEGF-A, previously shown to be regulated by SRSF1 phosphorylation by SRPK1." | 1.40 | Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. ( Bates, DO; Coupland, SE; Dean, R; Gammons, MV; Lucas, R; Oltean, S, 2014) |
| "Colorectal cancer is one of the most common malignancies in the world, and is generally treated more effectively by chemoradiotherapy rather than radiotherapy or chemotherapy alone." | 1.40 | The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells. ( Jung, WG; Kim, EH; Kim, MS, 2014) |
| "Sorafenib is a multi-kinase inhibitor that blocks cell proliferation and angiogenesis." | 1.39 | Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis. ( Fan, X; Haney, CR; Karczmar, GS; Markiewicz, E; Mustafi, D; Stadler, WM, 2013) |
| "Sorafenib was able to inhibit the expression of HIF-1α and VEGFA, and sorafenib was able to increase time to recurrence when used as an adjunct to RFA." | 1.39 | Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo. ( Huang, GL; Liu, GJ; Lü, MD; Wang, W; Xie, XH; Xie, XY; Xu, M; Xu, ZF; Zheng, SG; Zheng, YL, 2013) |
| "A primary culture of renal cell carcinoma cells (KMRM-S2) was established from an advanced renal cell carcinoma patient with cutaneous metastasis, who had not responded to sorafenib." | 1.39 | Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis. ( Ashida, S; Fukuhara, H; Inoue, K; Kamada, M; Karashima, T; Kuroda, N; Shuin, T; Taguchi, T; Tamura, K, 2013) |
| "Treatment with sorafenib led to decreased ERK phosphorylation, reduced cell viability and induction of apoptosis in HepT1 and HUH6 cells." | 1.38 | Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice. ( Armeanu-Ebinger, S; Dewerth, A; Eicher, C; Fuchs, J; Kirchner, B; Warmann, SW, 2012) |
| " Furthermore, the RAIN-Droplet model has facilitated the discovery of a novel pro-angiogenic capacity for sorafenib, which may impact the clinical application and dosing regimen of that drug." | 1.38 | RAIN-Droplet: a novel 3D in vitro angiogenesis model. ( Dong, Z; Nör, JE; Zeitlin, BD, 2012) |
| "The Morris Hepatoma (MH) and HepG2 cells were treated in vitro with sorafenib (1-10 μM) and erlotinib (1-5 μM) and evaluated for tumor cell viability, apoptosis, and target regulation." | 1.38 | Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. ( Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W, 2012) |
| "Patients receiving surgical treatment of endometriosis (n = 4) and control patients without endometriosis (n = 2) undergoing surgery for benign gynecologic diseases." | 1.38 | Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. ( Bussolati, B; Cassoni, P; Marchino, GL; Moggio, A; Pittatore, G; Revelli, A, 2012) |
| "Sorafenib is considered to be a potent inhibitor of tumor angiogenesis and neovascularization in various solid tumors." | 1.38 | Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors. ( Bartsch, DK; Buchholz, M; Fendrich, V; Holler, JP; Maschuw, K; Rehm, J; Slater, EP; Waldmann, J, 2012) |
| "After hepatic implantation of Morris Hepatoma (MH) cells, rats were randomly allocated to everolimus (5 mg/kg, 2×/week), sorafenib (7." | 1.37 | Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. ( Afthinos, M; Djonov, V; Dufour, JF; Hlushchuk, R; McSheehy, PM; Piguet, AC; Radojevic, V; Saar, B; St-Pierre, MV; Terracciano, L, 2011) |
| "Lung cancer is one of the most lethal tumors and, although standard chemotherapy produces clinical response, there has been little improvement in prognosis." | 1.37 | Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. ( Danesi, R; Del Tacca, M; Mey, V; Pasqualetti, G; Ricciardi, S, 2011) |
| " Taken together, the data suggest that premexetred and sorafenib act synergistically to enhance tumor killing via the promotion of a toxic form of autophagy that leads to activation of the intrinsic apoptosis pathway, and predict that combination treatment represents a future therapeutic option in the treatment of solid tumors." | 1.37 | Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. ( Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Moran, RG; Nephew, KP; Tang, Y, 2011) |
| "Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a standard of care in advanced HCC." | 1.37 | Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. ( Choo, SP; Chow, PK; Chung, AY; Huynh, H; Ong, R; Soo, KC; Tai, WM; Toh, HC, 2011) |
| "Sorafenib (SO) is a promising new multikinase inhibitor for treatment of advanced kidney and liver cancers." | 1.36 | Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. ( Baumann, B; Büchler, MW; Gladkich, J; Herr, I; Kallifatidis, G; Liu, L; Mattern, J; Rausch, V; Salnikov, AV; Schemmer, P; Wirth, T; Zöller, M, 2010) |
| " These combinations appear to be the most promising for in vivo pre-clinical studies, with a view to testing in melanoma patients as a continuous dosing strategy, due to the in vitro additive inhibitory effect on growth seen in both endothelial and cancer cells." | 1.36 | Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy. ( Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P, 2010) |
| " This study was to investigate the effect of rapamycin, alone and in combination with sorafenib, on HCC in vivo." | 1.35 | Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. ( Fan, J; Huang, XW; Qiu, SJ; Tang, ZY; Wang, Z; Yu, Y; Zhou, J, 2008) |
| "Caki-1, A498, and 786-0 human renal cell carcinoma (RCC) xenografts were implanted in 39 nude mice." | 1.35 | Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? ( Alsop, DC; Atkins, MB; Goldberg, SN; Lenkinski, RE; Marquis, RP; Pedrosa, I; Regan, M; Schor-Bardach, R; Signoretti, S; Solazzo, SA; Wang, X, 2009) |
| "Treatment with sorafenib resulted in a significant decrease of PP (p<0." | 1.35 | Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. ( Angermayr, B; Gangl, A; Mitterhauser, M; Peck-Radosavljevic, M; Reiberger, T; Rohr-Udilova, N; Schwabl, P, 2009) |
| "Everolimus is an orally administered, targeted therapy indicated for the treatment of advanced renal cell carcinoma." | 1.35 | Everolimus: in advanced renal cell carcinoma. ( Garnock-Jones, KP; Keating, GM, 2009) |
| "Sorafenib is able to inhibit their signal transduction, both in vitro and in vivo, displaying anti-tumoural activity, anti-angiogenic effects, and reducing metastatic colony formation in lungs." | 1.35 | Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. ( Aglietta, M; Alberghini, M; Bottos, A; Bruno, S; Bussolino, F; Camussi, G; Cavalloni, G; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Migliardi, G; Motta, M; Picci, P; Pignochino, Y; Tapparo, M; Torchio, B, 2009) |
| " In the PLC/PRF/5 xenograft model, sorafenib tosylate dosed at 10 mg/kg inhibited tumor growth by 49%." | 1.33 | Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. ( Cao, Y; Carter, C; Chen, C; Liu, L; Lynch, M; McNabola, A; Wilhelm, S; Wilkie, D; Zhang, X, 2006) |
| " Once daily oral dosing of BAY 43-9006 demonstrated broad-spectrum antitumor activity in colon, breast, and non-small-cell lung cancer xenograft models." | 1.32 | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. ( Adnane, L; Auclair, D; Bollag, G; Cao, Y; Carter, C; Chen, C; Eveleigh, D; Gawlak, S; Gedrich, R; Liu, L; Lynch, M; McHugh, M; McNabola, A; Post, LE; Riedl, B; Rong, H; Rowley, B; Shujath, J; Tang, L; Taylor, I; Trail, PA; Vincent, P; Voznesensky, A; Wilhelm, SM; Wilkie, D; Zhang, X, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.97) | 18.7374 |
| 1990's | 1 (0.49) | 18.2507 |
| 2000's | 55 (26.70) | 29.6817 |
| 2010's | 144 (69.90) | 24.3611 |
| 2020's | 4 (1.94) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, S | 3 |
| Park, JY | 1 |
| Lee, D | 1 |
| Seok, S | 1 |
| Kwon, YJ | 1 |
| Jang, TS | 1 |
| Kang, KS | 1 |
| Kim, KH | 1 |
| Yokota, S | 1 |
| Yonezawa, T | 1 |
| Momoi, Y | 1 |
| Maeda, S | 1 |
| Chai, MY | 1 |
| Kou, BX | 1 |
| Fu, Z | 1 |
| Wei, FL | 1 |
| Dou, SS | 1 |
| Chen, DX | 1 |
| Liu, XN | 1 |
| Kim, DH | 1 |
| Kang, HG | 1 |
| Park, HW | 1 |
| Lee, HW | 1 |
| Kim, D | 2 |
| Yoem, DH | 1 |
| Ahn, JH | 2 |
| Ha, E | 2 |
| You, WK | 2 |
| Lee, SH | 2 |
| Kim, SJ | 1 |
| Chun, KH | 1 |
| Yeom, DH | 1 |
| Lee, YS | 1 |
| Ryu, I | 1 |
| Sung, B | 1 |
| Lee, HB | 1 |
| Choi, YS | 1 |
| Gill, DM | 1 |
| Agarwal, N | 1 |
| Vaishampayan, U | 1 |
| Manzo, A | 1 |
| Montanino, A | 1 |
| Carillio, G | 1 |
| Costanzo, R | 1 |
| Sandomenico, C | 1 |
| Normanno, N | 1 |
| Piccirillo, MC | 1 |
| Daniele, G | 1 |
| Perrone, F | 1 |
| Rocco, G | 1 |
| Morabito, A | 1 |
| Yang, S | 1 |
| Lin, J | 2 |
| Lu, F | 2 |
| Han, Z | 1 |
| Fu, C | 1 |
| Gu, H | 1 |
| Hori, Y | 1 |
| Ito, K | 2 |
| Hamamichi, S | 1 |
| Ozawa, Y | 1 |
| Matsui, J | 1 |
| Umeda, IO | 1 |
| Fujii, H | 1 |
| Cao, YW | 1 |
| Liu, Y | 1 |
| Dong, Z | 2 |
| Guo, L | 1 |
| Kang, EH | 1 |
| Wang, YH | 1 |
| Zhang, W | 4 |
| Niu, HT | 1 |
| Huang, K | 1 |
| Zhao, ZM | 1 |
| Liu, HL | 1 |
| Sun, X | 2 |
| Lü, J | 1 |
| Tao, YY | 1 |
| Liu, CH | 2 |
| Yan, J | 1 |
| Tan, C | 1 |
| Gu, F | 1 |
| Jiang, J | 1 |
| Xu, M | 3 |
| Huang, X | 1 |
| Dai, Z | 3 |
| Wang, Z | 3 |
| Fan, J | 4 |
| Zhou, J | 5 |
| Pignochino, Y | 2 |
| Dell'Aglio, C | 1 |
| Basiricò, M | 1 |
| Capozzi, F | 1 |
| Soster, M | 1 |
| Marchiò, S | 1 |
| Bruno, S | 2 |
| Gammaitoni, L | 2 |
| Sangiolo, D | 1 |
| Torchiaro, E | 1 |
| D'Ambrosio, L | 1 |
| Fagioli, F | 2 |
| Ferrari, S | 2 |
| Alberghini, M | 2 |
| Picci, P | 2 |
| Aglietta, M | 2 |
| Grignani, G | 2 |
| Azad, N | 1 |
| Yu, M | 1 |
| Davidson, B | 1 |
| Choyke, P | 2 |
| Chen, CC | 1 |
| Wood, BJ | 1 |
| Venkatesan, A | 1 |
| Henning, R | 1 |
| Calvo, K | 1 |
| Minasian, L | 1 |
| Edelman, DC | 1 |
| Meltzer, P | 1 |
| Steinberg, SM | 2 |
| Annunziata, CM | 1 |
| Kohn, EC | 1 |
| Itzhaki, O | 1 |
| Greenberg, E | 1 |
| Shalmon, B | 1 |
| Kubi, A | 1 |
| Treves, AJ | 1 |
| Shapira-Frommer, R | 1 |
| Avivi, C | 1 |
| Ortenberg, R | 1 |
| Ben-Ami, E | 1 |
| Schachter, J | 1 |
| Besser, MJ | 1 |
| Markel, G | 1 |
| Awazu, Y | 1 |
| Nakamura, K | 1 |
| Mizutani, A | 1 |
| Kakoi, Y | 1 |
| Iwata, H | 1 |
| Yamasaki, S | 1 |
| Miyamoto, N | 1 |
| Imamura, S | 1 |
| Miki, H | 1 |
| Hori, A | 1 |
| Sampat, KR | 1 |
| O'Neil, B | 1 |
| Sacco, R | 1 |
| Faggioni, L | 1 |
| Bargellini, I | 1 |
| Ginanni, B | 1 |
| Battaglia, V | 1 |
| Romano, A | 1 |
| Bertini, M | 1 |
| Bresci, G | 1 |
| Bartolozzi, C | 1 |
| Chong, DQ | 1 |
| Tan, IB | 1 |
| Choo, SP | 3 |
| Toh, HC | 3 |
| Carlo-Stella, C | 2 |
| Locatelli, SL | 1 |
| Giacomini, A | 2 |
| Cleris, L | 1 |
| Saba, E | 1 |
| Righi, M | 2 |
| Guidetti, A | 1 |
| Gianni, AM | 2 |
| Zhang, K | 1 |
| Waxman, DJ | 1 |
| Zhu, XD | 3 |
| Sun, HC | 3 |
| Xu, HX | 2 |
| Kong, LQ | 1 |
| Chai, ZT | 1 |
| Lu, L | 1 |
| Zhang, JB | 2 |
| Gao, DM | 2 |
| Wang, WQ | 2 |
| Zhuang, PY | 2 |
| Wu, WZ | 2 |
| Wang, L | 2 |
| Tang, ZY | 4 |
| Wild, AT | 1 |
| Gandhi, N | 1 |
| Chettiar, ST | 1 |
| Aziz, K | 1 |
| Gajula, RP | 1 |
| Williams, RD | 1 |
| Kumar, R | 1 |
| Taparra, K | 1 |
| Zeng, J | 1 |
| Cades, JA | 1 |
| Velarde, E | 1 |
| Menon, S | 1 |
| Geschwind, JF | 1 |
| Cosgrove, D | 1 |
| Pawlik, TM | 1 |
| Maitra, A | 1 |
| Wong, J | 1 |
| Hales, RK | 1 |
| Torbenson, MS | 1 |
| Herman, JM | 1 |
| Tran, PT | 1 |
| Dokduang, H | 1 |
| Juntana, S | 1 |
| Techasen, A | 1 |
| Namwat, N | 1 |
| Yongvanit, P | 1 |
| Khuntikeo, N | 1 |
| Riggins, GJ | 1 |
| Loilome, W | 1 |
| Wunderlich, A | 1 |
| Khoruzhyk, M | 1 |
| Roth, S | 1 |
| Ramaswamy, A | 1 |
| Greene, BH | 1 |
| Doll, D | 1 |
| Bartsch, DK | 2 |
| Hoffmann, S | 1 |
| Pittatore, G | 2 |
| Moggio, A | 2 |
| Benedetto, C | 1 |
| Bussolati, B | 2 |
| Revelli, A | 2 |
| Miyahara, K | 1 |
| Nouso, K | 1 |
| Morimoto, Y | 1 |
| Takeuchi, Y | 1 |
| Hagihara, H | 1 |
| Kuwaki, K | 1 |
| Onishi, H | 1 |
| Ikeda, F | 1 |
| Miyake, Y | 1 |
| Nakamura, S | 1 |
| Shiraha, H | 1 |
| Takaki, A | 1 |
| Honda, M | 1 |
| Kaneko, S | 1 |
| Sato, T | 1 |
| Sato, S | 1 |
| Obi, S | 1 |
| Iwadou, S | 1 |
| Kobayashi, Y | 1 |
| Takaguchi, K | 1 |
| Kariyama, K | 1 |
| Takuma, Y | 1 |
| Takabatake, H | 1 |
| Yamamoto, K | 1 |
| Yoshiji, H | 1 |
| Noguchi, R | 1 |
| Namisaki, T | 1 |
| Moriya, K | 1 |
| Kitade, M | 1 |
| Aihara, Y | 1 |
| Douhara, A | 1 |
| Kawaratani, H | 1 |
| Nishimura, N | 1 |
| Fukui, H | 1 |
| Yang, W | 1 |
| Zhang, J | 4 |
| Hu, B | 1 |
| Wu, W | 1 |
| Venter, J | 1 |
| Alpini, G | 1 |
| Fallon, MB | 1 |
| Qin, Y | 1 |
| Lu, Y | 1 |
| Wang, R | 1 |
| Li, W | 1 |
| Qu, X | 1 |
| Tsuzuki, T | 1 |
| Sassa, N | 1 |
| Shimoyama, Y | 1 |
| Morikawa, T | 1 |
| Shiroki, R | 1 |
| Kuroda, M | 1 |
| Fukatsu, A | 1 |
| Kuwahara, K | 1 |
| Yoshino, Y | 1 |
| Hattori, R | 1 |
| Gotoh, M | 1 |
| Saif, MW | 1 |
| Abd-Alhaseeb, MM | 1 |
| Zaitone, SA | 1 |
| Abou-El-Ela, SH | 1 |
| Moustafa, YM | 1 |
| Shen, J | 1 |
| Sun, H | 1 |
| Meng, Q | 1 |
| Yin, Q | 2 |
| Zhang, Z | 2 |
| Yu, H | 2 |
| Li, Y | 2 |
| Scartozzi, M | 1 |
| Faloppi, L | 1 |
| Svegliati Baroni, G | 1 |
| Loretelli, C | 1 |
| Piscaglia, F | 3 |
| Iavarone, M | 1 |
| Toniutto, P | 1 |
| Fava, G | 1 |
| De Minicis, S | 1 |
| Mandolesi, A | 1 |
| Bianconi, M | 1 |
| Giampieri, R | 1 |
| Granito, A | 1 |
| Facchetti, F | 1 |
| Bitetto, D | 1 |
| Marinelli, S | 3 |
| Venerandi, L | 3 |
| Vavassori, S | 1 |
| Gemini, S | 1 |
| D'Errico, A | 1 |
| Colombo, M | 1 |
| Bolondi, L | 3 |
| Bearzi, I | 1 |
| Benedetti, A | 1 |
| Cascinu, S | 1 |
| Procopio, G | 1 |
| Testa, I | 1 |
| Iacovelli, R | 1 |
| Grassi, P | 1 |
| Verzoni, E | 1 |
| Garanzini, E | 1 |
| Colecchia, M | 1 |
| Torelli, T | 1 |
| De Braud, F | 1 |
| Qiu, YQ | 1 |
| Kang, XS | 1 |
| Ding, LM | 1 |
| Yu, W | 1 |
| Tan, FL | 1 |
| Deng, DF | 1 |
| Grépin, R | 1 |
| Ambrosetti, D | 1 |
| Marsaud, A | 1 |
| Gastaud, L | 1 |
| Amiel, J | 1 |
| Pedeutour, F | 1 |
| Pagès, G | 1 |
| Zhong, L | 1 |
| Fu, XY | 1 |
| Zou, C | 1 |
| Yang, LL | 1 |
| Zhou, S | 1 |
| Yang, J | 2 |
| Tang, Y | 3 |
| Cheng, C | 1 |
| Li, LL | 1 |
| Xiang, R | 1 |
| Chen, LJ | 1 |
| Chen, YZ | 1 |
| Wei, YQ | 1 |
| Yang, SY | 1 |
| Takami, H | 1 |
| Sugino, K | 1 |
| Salvatore, V | 2 |
| Baron Toaldo, M | 2 |
| Milazzo, M | 2 |
| Croci, L | 2 |
| Pecorelli, A | 1 |
| Palamà, C | 2 |
| Diana, A | 1 |
| Vandewynckel, YP | 1 |
| Laukens, D | 1 |
| Geerts, A | 2 |
| Vanhove, C | 1 |
| Descamps, B | 1 |
| Colle, I | 2 |
| Devisscher, L | 1 |
| Bogaerts, E | 1 |
| Paridaens, A | 1 |
| Verhelst, X | 1 |
| Van Steenkiste, C | 1 |
| Libbrecht, L | 2 |
| Lambrecht, BN | 1 |
| Janssens, S | 1 |
| Van Vlierberghe, H | 2 |
| Liu, L | 4 |
| Wu, CT | 1 |
| Xu, J | 1 |
| Liu, C | 1 |
| Long, J | 1 |
| Ni, QX | 1 |
| Yu, XJ | 1 |
| Gammons, MV | 1 |
| Lucas, R | 1 |
| Dean, R | 1 |
| Coupland, SE | 1 |
| Oltean, S | 1 |
| Bates, DO | 1 |
| Denorme, M | 1 |
| Yon, L | 1 |
| Roux, C | 1 |
| Gonzalez, BJ | 1 |
| Baudin, E | 1 |
| Anouar, Y | 1 |
| Dubessy, C | 1 |
| Sounni, NE | 1 |
| Cimino, J | 1 |
| Blacher, S | 1 |
| Primac, I | 1 |
| Truong, A | 1 |
| Mazzucchelli, G | 1 |
| Paye, A | 1 |
| Calligaris, D | 1 |
| Debois, D | 1 |
| De Tullio, P | 1 |
| Mari, B | 1 |
| De Pauw, E | 1 |
| Noel, A | 1 |
| Rijavec, E | 1 |
| Genova, C | 1 |
| Barletta, G | 1 |
| Biello, F | 1 |
| Dal Bello, MG | 1 |
| Coco, S | 1 |
| Truini, A | 1 |
| Vanni, I | 1 |
| Alama, A | 1 |
| Boccardo, F | 1 |
| Grossi, F | 1 |
| Cipone, M | 1 |
| Ma, L | 1 |
| Li, G | 1 |
| Zhu, H | 1 |
| Dong, X | 1 |
| Zhao, D | 1 |
| Jiang, X | 1 |
| Li, J | 1 |
| Qiao, H | 1 |
| Ni, S | 1 |
| Kim, EH | 1 |
| Kim, MS | 1 |
| Jung, WG | 1 |
| Nagel, C | 1 |
| Armeanu-Ebinger, S | 3 |
| Dewerth, A | 3 |
| Warmann, SW | 3 |
| Fuchs, J | 3 |
| Yu, P | 1 |
| Ye, L | 2 |
| Wang, H | 3 |
| Du, G | 1 |
| Zuo, Y | 1 |
| Tian, J | 2 |
| Cao, H | 1 |
| Wang, Y | 1 |
| He, X | 1 |
| Chen, Y | 2 |
| Huang, Y | 1 |
| Chen, L | 1 |
| Gu, W | 1 |
| Yamamoto, Y | 1 |
| De Velasco, MA | 1 |
| Kura, Y | 1 |
| Nozawa, M | 1 |
| Hatanaka, Y | 1 |
| Oki, T | 1 |
| Ozeki, T | 1 |
| Shimizu, N | 1 |
| Minami, T | 1 |
| Yoshimura, K | 1 |
| Yoshikawa, K | 1 |
| Nishio, K | 1 |
| Uemura, H | 1 |
| Groß, C | 1 |
| Steiger, K | 1 |
| Sayyed, S | 1 |
| Heid, I | 1 |
| Feuchtinger, A | 1 |
| Walch, A | 1 |
| Heß, J | 1 |
| Unger, K | 1 |
| Zitzelsberger, H | 1 |
| Settles, M | 1 |
| Schlitter, AM | 1 |
| Dworniczak, J | 1 |
| Altomonte, J | 1 |
| Ebert, O | 1 |
| Schwaiger, M | 1 |
| Rummeny, E | 1 |
| Steingötter, A | 1 |
| Esposito, I | 1 |
| Braren, R | 1 |
| Kim, MN | 1 |
| Ro, SW | 1 |
| Kim, DY | 2 |
| Kim, da Y | 1 |
| Cho, KJ | 1 |
| Park, JH | 1 |
| Lim, HY | 1 |
| Han, KH | 2 |
| Pollom, EL | 1 |
| Deng, L | 1 |
| Pai, RK | 1 |
| Brown, JM | 1 |
| Giaccia, A | 1 |
| Loo, BW | 1 |
| Shultz, DB | 1 |
| Le, QT | 1 |
| Koong, AC | 1 |
| Chang, DT | 1 |
| Lu, YY | 1 |
| Wang, JJ | 1 |
| Zhang, XK | 1 |
| Li, WB | 1 |
| Guo, XL | 1 |
| Waidmann, O | 1 |
| Trojan, J | 1 |
| Leconte, M | 1 |
| Santulli, P | 1 |
| Chouzenoux, S | 1 |
| Marcellin, L | 1 |
| Cerles, O | 1 |
| Chapron, C | 1 |
| Dousset, B | 1 |
| Batteux, F | 1 |
| Liu, JY | 1 |
| Chiang, T | 1 |
| Chern, GG | 1 |
| Lin, TT | 1 |
| Gao, DY | 1 |
| Djokovic, D | 1 |
| Trindade, A | 1 |
| Gigante, J | 1 |
| Pinho, M | 1 |
| Harris, AL | 2 |
| Duarte, A | 1 |
| Devapatla, B | 1 |
| Sharma, A | 2 |
| Woo, S | 1 |
| Knod, JL | 1 |
| Crawford, K | 1 |
| Dusing, M | 1 |
| Frischer, JS | 1 |
| Wang, W | 2 |
| Ni, Y | 1 |
| Yao, Z | 1 |
| Zhang, C | 1 |
| Ning, Z | 1 |
| Xu, L | 1 |
| Zhu, X | 1 |
| Meng, Z | 1 |
| Schneider, TC | 1 |
| Kapiteijn, E | 1 |
| van Wezel, T | 1 |
| Smit, JWA | 1 |
| van der Hoeven, JJM | 1 |
| Morreau, H | 1 |
| Bretagne, M | 1 |
| Boudou-Rouquette, P | 1 |
| Huillard, O | 1 |
| Thomas-Schoemann, A | 1 |
| Chahwakilian, A | 1 |
| Orvoen, G | 1 |
| Arrondeau, J | 1 |
| Tlemsani, C | 1 |
| Cessot, A | 1 |
| Cabanes, L | 1 |
| Blanchet, B | 1 |
| Coriat, R | 1 |
| Alexandre, J | 1 |
| Goldwasser, F | 1 |
| Jayson, GC | 1 |
| Kerbel, R | 1 |
| Ellis, LM | 1 |
| Kaya, TT | 1 |
| Altun, A | 1 |
| Turgut, NH | 1 |
| Ataseven, H | 1 |
| Koyluoglu, G | 1 |
| Kuczynski, EA | 2 |
| Yin, M | 1 |
| Bar-Zion, A | 1 |
| Lee, CR | 2 |
| Butz, H | 1 |
| Man, S | 2 |
| Daley, F | 1 |
| Vermeulen, PB | 1 |
| Yousef, GM | 1 |
| Foster, FS | 1 |
| Reynolds, AR | 2 |
| Kerbel, RS | 3 |
| Salavert, F | 1 |
| Hidago, MR | 1 |
| Amadoz, A | 1 |
| Çubuk, C | 1 |
| Medina, I | 1 |
| Crespo, D | 1 |
| Carbonell-Caballero, J | 1 |
| Dopazo, J | 1 |
| Lewandowski, RJ | 1 |
| Andreoli, JM | 1 |
| Hickey, R | 1 |
| Kallini, JR | 1 |
| Gabr, A | 1 |
| Baker, T | 1 |
| Kircher, S | 1 |
| Salem, R | 1 |
| Kulik, L | 1 |
| Yang, SH | 1 |
| Han, ZH | 1 |
| Fu, CX | 1 |
| Lv, P | 1 |
| Liu, H | 1 |
| Kong, WT | 1 |
| Cai, H | 1 |
| Zhang, XL | 1 |
| Wang, WP | 1 |
| Martinez-Quetglas, I | 1 |
| Pinyol, R | 1 |
| Dauch, D | 1 |
| Torrecilla, S | 1 |
| Tovar, V | 1 |
| Moeini, A | 1 |
| Alsinet, C | 1 |
| Portela, A | 1 |
| Rodriguez-Carunchio, L | 1 |
| Solé, M | 1 |
| Lujambio, A | 1 |
| Villanueva, A | 1 |
| Thung, S | 1 |
| Esteller, M | 1 |
| Zender, L | 1 |
| Llovet, JM | 1 |
| Woo, HY | 1 |
| Yoo, SY | 1 |
| Heo, J | 1 |
| Samsel, PA | 1 |
| Narov, K | 1 |
| Jones, A | 1 |
| Gallacher, D | 1 |
| Gallacher, J | 1 |
| Sampson, JR | 1 |
| Shen, MH | 1 |
| Ohata, Y | 1 |
| Shimada, S | 1 |
| Akiyama, Y | 1 |
| Mogushi, K | 1 |
| Nakao, K | 1 |
| Matsumura, S | 1 |
| Aihara, A | 1 |
| Mitsunori, Y | 1 |
| Ban, D | 1 |
| Ochiai, T | 1 |
| Kudo, A | 1 |
| Arii, S | 1 |
| Tanabe, M | 1 |
| Tanaka, S | 1 |
| Tran, MA | 1 |
| Smith, CD | 2 |
| Kester, M | 1 |
| Robertson, GP | 2 |
| Blumenschein, G | 1 |
| Sessa, C | 1 |
| Guibal, A | 1 |
| Del Conte, G | 1 |
| Rüegg, C | 1 |
| Qiu, SJ | 2 |
| Yu, Y | 2 |
| Huang, XW | 2 |
| Yau, T | 1 |
| Chan, P | 1 |
| Epstein, R | 1 |
| Poon, RT | 1 |
| Greten, TF | 1 |
| Manns, MP | 1 |
| Malek, N | 1 |
| Boucher, E | 1 |
| Forner, A | 1 |
| Reig, M | 1 |
| Bruix, J | 1 |
| Tsai, JH | 1 |
| Lee, WM | 2 |
| Oseini, AM | 1 |
| Roberts, LR | 1 |
| Elfiky, AA | 1 |
| Rosenberg, JE | 1 |
| Komuro, A | 1 |
| Yashiro, M | 1 |
| Iwata, C | 1 |
| Morishita, Y | 1 |
| Johansson, E | 1 |
| Matsumoto, Y | 1 |
| Watanabe, A | 1 |
| Aburatani, H | 1 |
| Miyoshi, H | 1 |
| Kiyono, K | 1 |
| Shirai, YT | 1 |
| Suzuki, HI | 1 |
| Hirakawa, K | 1 |
| Kano, MR | 1 |
| Miyazono, K | 1 |
| Domont, J | 1 |
| Massard, C | 2 |
| Lassau, N | 2 |
| Armand, JP | 2 |
| Le Cesne, A | 1 |
| Soria, JC | 1 |
| Snider, KL | 1 |
| Maitland, ML | 2 |
| Kelly, RJ | 2 |
| Billemont, B | 2 |
| Rixe, O | 2 |
| Schor-Bardach, R | 1 |
| Alsop, DC | 1 |
| Pedrosa, I | 1 |
| Solazzo, SA | 1 |
| Wang, X | 1 |
| Marquis, RP | 1 |
| Atkins, MB | 2 |
| Regan, M | 2 |
| Signoretti, S | 2 |
| Lenkinski, RE | 1 |
| Goldberg, SN | 2 |
| Shibuya, M | 1 |
| Cortés-Funes, H | 1 |
| Yu, L | 1 |
| Dudley, AC | 1 |
| Klagsbrun, M | 1 |
| Xiong, YQ | 1 |
| Qin, LX | 1 |
| Lavazza, C | 1 |
| Sia, D | 1 |
| Reiberger, T | 1 |
| Angermayr, B | 1 |
| Schwabl, P | 1 |
| Rohr-Udilova, N | 2 |
| Mitterhauser, M | 1 |
| Gangl, A | 1 |
| Peck-Radosavljevic, M | 2 |
| Song, IH | 1 |
| Garnock-Jones, KP | 1 |
| Keating, GM | 1 |
| Huynh, H | 3 |
| Ngo, VC | 1 |
| Koong, HN | 1 |
| Poon, D | 1 |
| Thng, CH | 1 |
| Chow, P | 1 |
| Ong, HS | 1 |
| Chung, A | 1 |
| Goh, BC | 1 |
| Smith, PD | 1 |
| Soo, KC | 2 |
| Cabrera, R | 1 |
| Nelson, DR | 1 |
| Cavalloni, G | 1 |
| Motta, M | 1 |
| Tapparo, M | 1 |
| Bottos, A | 1 |
| Migliardi, G | 1 |
| Camussi, G | 1 |
| Torchio, B | 1 |
| Bussolino, F | 1 |
| Maksimovic, O | 1 |
| Schraml, C | 1 |
| Hartmann, JT | 1 |
| Bitzer, M | 1 |
| Claussen, CD | 1 |
| Pintoffl, J | 1 |
| Horger, M | 1 |
| Alfano, RW | 1 |
| Leppla, SH | 1 |
| Liu, S | 1 |
| Bugge, TH | 1 |
| Ortiz, JM | 1 |
| Lairmore, TC | 1 |
| Duesbery, NS | 1 |
| Mitchell, IC | 1 |
| Nwariaku, F | 1 |
| Frankel, AE | 1 |
| Tong, TQ | 1 |
| Rohde, D | 1 |
| Peter, S | 1 |
| Tang, TC | 1 |
| Xu, P | 1 |
| Barrascout, E | 1 |
| Medioni, J | 1 |
| Scotte, F | 1 |
| Ayllon, J | 1 |
| Mejean, A | 1 |
| Cuenod, CA | 1 |
| Tartour, E | 1 |
| Elaidi, R | 1 |
| Oudard, S | 1 |
| Siegelin, MD | 1 |
| Raskett, CM | 1 |
| Gilbert, CA | 1 |
| Ross, AH | 1 |
| Altieri, DC | 1 |
| Salas, S | 1 |
| Huynh, T | 1 |
| Deville, JL | 1 |
| Duffaud, F | 1 |
| Rausch, V | 1 |
| Kallifatidis, G | 1 |
| Baumann, B | 1 |
| Mattern, J | 1 |
| Gladkich, J | 1 |
| Wirth, T | 1 |
| Schemmer, P | 1 |
| Büchler, MW | 1 |
| Zöller, M | 1 |
| Salnikov, AV | 1 |
| Herr, I | 1 |
| Shen, YC | 2 |
| Hsu, C | 2 |
| Cheng, AL | 2 |
| Bono, AV | 1 |
| Pannellini, T | 1 |
| Liberatore, M | 1 |
| Montironi, R | 1 |
| Cunico, SC | 1 |
| Cheng, L | 1 |
| Sasso, F | 1 |
| Musiani, P | 1 |
| Iezzi, M | 1 |
| Pinto, A | 1 |
| Redondo, A | 1 |
| Zamora, P | 1 |
| Castelo, B | 1 |
| Espinosa, E | 1 |
| Murray, A | 1 |
| Little, SJ | 1 |
| Stanley, P | 1 |
| Maraveyas, A | 1 |
| Cawkwell, L | 1 |
| Lemasson, B | 1 |
| Serduc, R | 1 |
| Maisin, C | 1 |
| Bouchet, A | 1 |
| Coquery, N | 1 |
| Robert, P | 1 |
| Le Duc, G | 1 |
| Troprès, I | 1 |
| Rémy, C | 1 |
| Barbier, EL | 1 |
| Leguerney, I | 1 |
| Koscielny, S | 1 |
| Rodrigues, M | 1 |
| Rouffiac, V | 1 |
| Benatsou, B | 1 |
| Thalmensi, J | 1 |
| Bawa, O | 1 |
| Opolon, P | 1 |
| Peronneau, P | 1 |
| Roche, A | 1 |
| Nielsen, DL | 1 |
| Andersson, M | 1 |
| Andersen, JL | 1 |
| Kamby, C | 1 |
| Cai, J | 1 |
| Han, S | 1 |
| Qing, R | 1 |
| Liao, D | 1 |
| Law, B | 1 |
| Boulton, ME | 1 |
| Carroll, AR | 1 |
| Coleman, RL | 1 |
| Sood, AK | 1 |
| Rajan, A | 1 |
| Force, J | 1 |
| Lopez-Chavez, A | 1 |
| Keen, C | 1 |
| Cao, L | 1 |
| Turkbey, B | 1 |
| Raffeld, M | 1 |
| Xi, L | 1 |
| Wright, JJ | 1 |
| Kummar, S | 1 |
| Gutierrez, M | 1 |
| Giaccone, G | 1 |
| Hsu, CY | 1 |
| Yu, CW | 1 |
| Hu, FC | 1 |
| Hsu, CH | 1 |
| Chen, BB | 1 |
| Wei, SY | 1 |
| Shih, TT | 1 |
| Yuen, JS | 1 |
| Sim, MY | 1 |
| Siml, HG | 1 |
| Chong, TW | 1 |
| Lau, WK | 1 |
| Cheng, CW | 1 |
| Maráz, A | 1 |
| Piguet, AC | 2 |
| Saar, B | 1 |
| Hlushchuk, R | 1 |
| St-Pierre, MV | 1 |
| McSheehy, PM | 1 |
| Radojevic, V | 1 |
| Afthinos, M | 1 |
| Terracciano, L | 1 |
| Djonov, V | 1 |
| Dufour, JF | 2 |
| Pasqualetti, G | 1 |
| Ricciardi, S | 1 |
| Mey, V | 1 |
| Del Tacca, M | 1 |
| Danesi, R | 1 |
| Yadav, A | 1 |
| Kumar, B | 1 |
| Teknos, TN | 1 |
| Kumar, P | 1 |
| Okines, AF | 1 |
| Cunningham, D | 1 |
| Hu, J | 1 |
| Tan, CJ | 1 |
| Bareford, MD | 1 |
| Hamed, HA | 1 |
| Cruickshanks, N | 1 |
| Burow, ME | 1 |
| Fisher, PB | 1 |
| Moran, RG | 1 |
| Nephew, KP | 1 |
| Grant, S | 1 |
| Dent, P | 1 |
| Tai, WM | 1 |
| Chung, AY | 1 |
| Chow, PK | 1 |
| Ong, R | 1 |
| Liu, Q | 1 |
| Mier, JW | 1 |
| Panka, DJ | 1 |
| Podar, K | 1 |
| Anderson, KC | 1 |
| Choi, HE | 1 |
| Yoo, MS | 1 |
| Choi, JH | 1 |
| Lee, JY | 1 |
| Kim, JH | 2 |
| Lee, JK | 1 |
| Kim, GI | 1 |
| Park, Y | 1 |
| Chi, YH | 1 |
| Paik, SH | 1 |
| Lee, JH | 1 |
| Lee, KT | 1 |
| Gamstätter, T | 1 |
| Weinmann, A | 1 |
| Schadmand-Fischer, S | 1 |
| Spies, PR | 1 |
| Niederle, IM | 1 |
| Schuchmann, M | 1 |
| Galle, PR | 1 |
| Wörns, MA | 1 |
| Wellbrock, J | 1 |
| Fiedler, W | 1 |
| Young, RJ | 1 |
| Reed, MW | 1 |
| Kakodkar, NC | 1 |
| Peddinti, RR | 1 |
| Tian, Y | 1 |
| Guerrero, LJ | 1 |
| Chlenski, A | 1 |
| Yang, Q | 1 |
| Salwen, HR | 1 |
| Cohn, SL | 1 |
| Eicher, C | 2 |
| Kirchner, B | 1 |
| Matsuda, Y | 1 |
| Fukumoto, M | 1 |
| Allavena, P | 1 |
| Mantovani, A | 1 |
| Martin, B | 1 |
| Edeline, J | 1 |
| Patard, JJ | 2 |
| Oger, E | 1 |
| Jouan, F | 1 |
| Boulanger, G | 1 |
| Zerrouki, S | 1 |
| Vigneau, C | 1 |
| Rioux-Leclercq, N | 1 |
| Török, S | 1 |
| Döme, B | 1 |
| Xie, B | 1 |
| Wang, DH | 1 |
| Spechler, SJ | 1 |
| Zeitlin, BD | 1 |
| Nör, JE | 1 |
| Chung, AS | 1 |
| Kowanetz, M | 1 |
| Wu, X | 1 |
| Zhuang, G | 1 |
| Ngu, H | 1 |
| Finkle, D | 1 |
| Komuves, L | 1 |
| Peale, F | 1 |
| Ferrara, N | 1 |
| Sieghart, W | 1 |
| Pinter, M | 1 |
| Dauser, B | 1 |
| Prager, G | 1 |
| Hayden, H | 1 |
| Dienes, HP | 1 |
| Spârchez, Z | 1 |
| Moschouris, H | 1 |
| Malagari, K | 1 |
| Gkoutzios, P | 1 |
| Kalokairinou, M | 1 |
| Stamatiou, K | 1 |
| Chatzimichail, K | 1 |
| Kornezos, I | 1 |
| Karagiannis, E | 1 |
| Kiltenis, M | 1 |
| Papadaki, MG | 1 |
| Gold, KA | 1 |
| Kim, E | 1 |
| Yang, Y | 1 |
| Jiang, H | 1 |
| Gao, H | 1 |
| Kong, J | 1 |
| Zhang, P | 2 |
| Hu, S | 1 |
| Shi, B | 1 |
| Yao, M | 1 |
| Li, Z | 1 |
| Cervello, M | 1 |
| Bachvarov, D | 1 |
| Lampiasi, N | 1 |
| Cusimano, A | 1 |
| Azzolina, A | 1 |
| McCubrey, JA | 1 |
| Montalto, G | 1 |
| Reddy, S | 1 |
| Raffin, M | 1 |
| Kaklamani, V | 1 |
| Pazo-Cid, RA | 1 |
| Lanzuela, M | 1 |
| Esquerdo, G | 1 |
| Pérez-Gracia, JL | 1 |
| Antón, A | 1 |
| Amigo, G | 1 |
| Trufero, JM | 1 |
| García-Otín, AL | 1 |
| Martín-Duque, P | 1 |
| Matsui, O | 1 |
| Haney, CR | 1 |
| Fan, X | 1 |
| Markiewicz, E | 1 |
| Mustafi, D | 1 |
| Karczmar, GS | 1 |
| Stadler, WM | 1 |
| Liu, LP | 1 |
| Ho, RL | 1 |
| Chen, GG | 1 |
| Lai, PB | 1 |
| Ang, C | 1 |
| O'Reilly, EM | 1 |
| Abou-Alfa, GK | 1 |
| Cassoni, P | 1 |
| Marchino, GL | 1 |
| Heindryckx, F | 1 |
| Coulon, S | 1 |
| Terrie, E | 1 |
| Casteleyn, C | 1 |
| Stassen, JM | 1 |
| Allemeersch, J | 1 |
| Carmeliet, P | 1 |
| Xie, XH | 1 |
| Xie, XY | 1 |
| Xu, ZF | 1 |
| Liu, GJ | 1 |
| Zheng, YL | 1 |
| Huang, GL | 1 |
| Zheng, SG | 1 |
| Lü, MD | 1 |
| Yao, JW | 1 |
| Sun, W | 1 |
| Chen, J | 1 |
| Xu, WF | 1 |
| Thomale, J | 1 |
| Ellerkamp, V | 1 |
| Hildenbrand, S | 1 |
| Hammond, E | 1 |
| Brandt, R | 1 |
| Dredge, K | 1 |
| Fendrich, V | 1 |
| Maschuw, K | 1 |
| Rehm, J | 1 |
| Buchholz, M | 1 |
| Holler, JP | 1 |
| Slater, EP | 1 |
| Waldmann, J | 1 |
| Karashima, T | 1 |
| Fukuhara, H | 1 |
| Tamura, K | 1 |
| Ashida, S | 1 |
| Kamada, M | 1 |
| Inoue, K | 1 |
| Taguchi, T | 1 |
| Kuroda, N | 1 |
| Shuin, T | 1 |
| Wilhelm, SM | 1 |
| Carter, C | 3 |
| Tang, L | 1 |
| Wilkie, D | 2 |
| McNabola, A | 2 |
| Rong, H | 1 |
| Chen, C | 2 |
| Zhang, X | 2 |
| Vincent, P | 1 |
| McHugh, M | 1 |
| Cao, Y | 2 |
| Shujath, J | 1 |
| Gawlak, S | 1 |
| Eveleigh, D | 1 |
| Rowley, B | 1 |
| Adnane, L | 1 |
| Lynch, M | 2 |
| Auclair, D | 1 |
| Taylor, I | 1 |
| Gedrich, R | 1 |
| Voznesensky, A | 1 |
| Riedl, B | 1 |
| Post, LE | 1 |
| Bollag, G | 1 |
| Trail, PA | 1 |
| Trivedi, NR | 1 |
| Zimmerman, MA | 1 |
| Tuveson, DA | 1 |
| Sridhar, SS | 1 |
| Hedley, D | 1 |
| Siu, LL | 1 |
| Herbst, RS | 1 |
| Onn, A | 1 |
| Sandler, A | 1 |
| Wakelee, HA | 1 |
| Schiller, JH | 1 |
| Zakarija, A | 1 |
| Soff, G | 1 |
| Rini, BI | 4 |
| Murphy, DA | 1 |
| Makonnen, S | 1 |
| Lassoued, W | 1 |
| Feldman, MD | 1 |
| Wilhelm, S | 1 |
| Schneider, BP | 1 |
| Sledge, GW | 1 |
| McKeage, K | 1 |
| Wagstaff, AJ | 1 |
| Silay, MS | 1 |
| Miroglu, C | 1 |
| Eichhorn, ME | 1 |
| Kleespies, A | 1 |
| Angele, MK | 1 |
| Jauch, KW | 1 |
| Bruns, CJ | 1 |
| Choueiri, TK | 1 |
| Garcia, JA | 1 |
| Elson, P | 1 |
| Khasawneh, M | 1 |
| Usman, S | 1 |
| Golshayan, AR | 1 |
| Baz, RC | 1 |
| Wood, L | 1 |
| Bukowski, RM | 1 |
| Cabebe, E | 1 |
| Wakelee, H | 1 |
| Mangiameli, DP | 1 |
| Blansfield, JA | 1 |
| Kachala, S | 1 |
| Lorang, D | 1 |
| Schafer, PH | 1 |
| Muller, GW | 1 |
| Stirling, DI | 1 |
| Libutti, SK | 1 |
| Hakimé, A | 1 |
| Hines-Peralta, A | 1 |
| Peddi, H | 1 |
| Sukhatme, VP | 1 |
| Bodrogi, I | 1 |
| Ropert, S | 1 |
| Mir, O | 1 |
| Méric, JB | 1 |
| Izzedine, H | 1 |
| Taillade, L | 1 |
| Sultan-Amar, V | 1 |
| Quesada, AR | 1 |
| Medina, MA | 1 |
| Alba, E | 1 |
| Pouessel, D | 2 |
| Culine, S | 2 |
| Verhoest, G | 1 |
| Chi, KN | 1 |
| Ellard, SL | 1 |
| Hotte, SJ | 1 |
| Czaykowski, P | 1 |
| Moore, M | 1 |
| Ruether, JD | 1 |
| Schell, AJ | 1 |
| Taylor, S | 1 |
| Hansen, C | 1 |
| Gauthier, I | 1 |
| Walsh, W | 1 |
| Seymour, L | 1 |
| Flaherty, KT | 1 |
| Rosen, MA | 1 |
| Heitjan, DF | 1 |
| Gallagher, ML | 1 |
| Schwartz, B | 1 |
| Schnall, MD | 1 |
| O'Dwyer, PJ | 1 |
| Petrelli, A | 1 |
| Giordano, S | 1 |
| Lee, CB | 1 |
| Socinski, MA | 1 |
| Horsman, MR | 1 |
| Khalil, AA | 1 |
| Chaplin, DJ | 1 |
| Overgaard, J | 1 |
| Begg, AC | 1 |
| Hofland, I | 1 |
| Van Der Pavert, I | 1 |
| Van Der Schueren, B | 1 |
| Haustermans, K | 1 |
| Wouters, BG | 1 |
| Weppler, SA | 1 |
| Koritzinsky, M | 1 |
| Landuyt, W | 1 |
| Nuyts, S | 1 |
| Theys, J | 1 |
| Chiu, RK | 1 |
| Lambin, P | 1 |
| Kull, FC | 1 |
| Brent, DA | 1 |
| Parikh, I | 1 |
| Cuatrecasas, P | 1 |
| Collins, TM | 1 |
| Denish, A | 1 |
| Sheffield, J | 1 |
| Mitra, A | 1 |
| Stueber, K | 1 |
| Smith, YR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Dose-escalation and Expansion Phase 1/2a Clinical Trial to Assess the Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and the Anti-tumor Efficacy of NOV1501 (ABL001) in Patients With Advanced Solid Tumors[NCT03292783] | Phase 1 | 45 participants (Actual) | Interventional | 2017-09-18 | Completed | ||
| Italian Multicentric Prospective Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib[NCT02786342] | 160 participants (Anticipated) | Observational | 2016-02-15 | Active, not recruiting | |||
| Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)[NCT05372302] | 100 participants (Anticipated) | Observational | 2021-07-08 | Recruiting | |||
| caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)[NCT03354884] | Phase 2 | 23 participants (Actual) | Interventional | 2018-01-12 | Completed | ||
| Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients[NCT03023124] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-03-04 | Recruiting | ||
| A Phase 1/2 Study of AZD6244 in Combination With Sorafenib in Advanced Hepatocellular Carcinoma[NCT01029418] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to The phase II portion was not conducted due to funding issue.) | ||
| A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846] | Phase 2/Phase 3 | 12 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| Phase II Study of Bay 43-9006 (Sorafenib) With Evaluation of RAS Signal Pathway in Patients With Relapsed Non-Small Cell Lung Cancer[NCT00098254] | Phase 2 | 37 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma[NCT00464919] | Phase 2 | 50 participants (Anticipated) | Interventional | 2007-04-30 | Completed | ||
| The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study[NCT03212625] | Phase 4 | 288 participants (Actual) | Interventional | 2016-01-28 | Completed | ||
| Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma[NCT02733809] | Phase 4 | 40 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Angiogenesis Inhibitors and Hypertension: Clinical Aspects[NCT00511511] | 80 participants (Anticipated) | Observational | 2007-08-31 | Completed | |||
| Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839] | Phase 2 | 21 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
| Randomized, Double-Blind, Placebo-Controlled, Phase II Trial Of Short Course Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized (3.5 to 7cm) Hepatocellular Cancer[NCT00813293] | Phase 2 | 20 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Phase II Study Of BAY 43-9006 (NSC 724772; CTEP IND# 69,896) In Patients With Hormone Refractory Prostate Cancer[NCT00093457] | Phase 2 | 28 participants (Actual) | Interventional | 2004-08-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Time between the first day of treatment to the days of death. (NCT00098254)
Timeframe: 17 months
| Intervention | months (Median) |
|---|---|
| BAY 43-9006 (Sorafenib) | 11.6 |
"Time between the first day of treatment to the day of disease progression. Progressive disease is at least a 20% increase in the sum of the longest diameter of target lesions.~Appearance of one or more new lesions and/or unequivocal progressions of existing non-target lesions." (NCT00098254)
Timeframe: 17 months
| Intervention | months (Median) |
|---|---|
| BAY 43-9006 (Sorafenib) | 3.4 |
Percentage of participants with response rate = CR + PR. Response will be evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR (complete response) is the disappearance of all target lesions; PR (partial response) is a 30% decrease in the sum of the longest diameter of target lesions; PD (progressive disease) is a 20% increase in the sum of the longest diameter of target lesions; and SD (stable disease) are small changes that do not meet the above criteria. Please see the Protocol Link module for additional information about RECIST if desired. (NCT00098254)
Timeframe: 17 months
| Intervention | percentage of participants (Number) |
|---|---|
| BAY 43-9006 (Sorafenib) | 6 |
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00098254)
Timeframe: 5 1/2 years
| Intervention | Participants (Number) |
|---|---|
| BAY 43-9006 (Sorafenib) | 37 |
Mutational analysis of these genes was performed on paraffin-imbedded tissue blocks from prior pathologic specimens. Disease control rate was correlated with KRAS mutational status. Disease control rate was defined as complete remission (CR) + partial remission (PR)+ stable disease (SD). (NCT00098254)
Timeframe: 42 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| DCR observed in KRAS mutant participants | DCR observed in KRAS wild-type participants | DCR observed in EGFR mutant participants | DCR observed in EGFR wild-type participants | |
| BAY 43-9006 (Sorafenib) | 60 | 71 | 40 | 69 |
Serial plasma samples were collected from all patients and cytokine levels were measured. The concentrations of the cytokines were determined with recombinant standards and expressed as picograms per milliliter (pg/ml). (NCT00098254)
Timeframe: 54 days
| Intervention | pg/ml (Median) | |||
|---|---|---|---|---|
| VEGF | sVEGFRI | PLGF | bFGF | |
| BAY 43-9006 (Sorafenib) | 101 | 115 | 19 | 6 |
Serum plasma is collected at the beginning of each cycle during the course of the study and analyzed by the enzyme-linked immunosorbent assay (ELISA). (NCT00098254)
Timeframe: 42 months
| Intervention | months (Median) | |
|---|---|---|
| Overall survival for bFGF day 0<6 pg/ml | Overall survival for bFGF day 0>6 pg/ml | |
| BAY 43-9006 (Sorafenib) | 15.4 | 5.5 |
Difference in placental derived growth factor (PLGF) between day 28 and day 0 of < 11 pg/ml vs. > 12 pg/ml. (NCT00098254)
Timeframe: 17 months
| Intervention | months (Median) | |
|---|---|---|
| PLGF ,< 11 pg/ml | PLGF > 12 pg/ml | |
| BAY 43-9006 (Sorafenib) | 6.6 | 15.6 |
DCE-MRI was used to evaluate changes (e.g. decrease/increase in Ve, Ktrans, Kep value) in vascularity and quality of index lesions to provide early indication of treatment effect before changes in size can be perceived on CT. Changes were reflected in a decrease/increase of Ve, Ktrans, or Kep (Kep, Ve, Ktrans measurements at day 0, day 14 and the difference between the day 14 and the day 0 measurements (day 14-day 0). (NCT00098254)
Timeframe: 59 months
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| percentage of pts with an increase in Ktrans orKep | percentage of pts with an decrease in Ktrans orKep | Percentage of pts with an increase or decrease-Ve | |
| BAY 43-9006 (Sorafenib) | 19 | 81 | 0 |
Serum plasma is collected at the beginning of each cycle during the course of the study and analyzed by the enzyme-linked immunosorbent assay (ELISA). (NCT00098254)
Timeframe: 17 months
| Intervention | months (Median) | |
|---|---|---|
| Progression free survival for bFGF day 28<6 pg/ml | Progression free survival for bFGF day 28>6 pg/ml | |
| BAY 43-9006 (Sorafenib) | 4.4 | 1.8 |
Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 45 |
Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 95 |
The size of the coagulation zone was determined on CT imaging obtained after RFA for the single index tumor. (NCT00813293)
Timeframe: Up to day 50 from study enrollment (target 30 days after RFA)
| Intervention | millimeters (Mean) |
|---|---|
| Sorafenib | 42.4 |
| Placebo | 44.1 |
The size of the coagulation zone was determined on CT imaging obtained after RFA for the single index tumor. (NCT00813293)
Timeframe: Up to day 50 from study enrollment (target 30 days after RFA)
| Intervention | millimeters (Mean) |
|---|---|
| Sorafenib | 36.0 |
| Placebo | 35.1 |
The size of the coagulation zone was determined on CT imaging obtained after RFA for the single index tumor. (NCT00813293)
Timeframe: Up to day 50 from study enrollment (target 30 days after RFA)
| Intervention | centimeters^3 (Mean) |
|---|---|
| Sorafenib | 30.7 |
| Placebo | 30.5 |
Feasibility rate is defined as the percentage of participants completing radiofrequency ablation following 9 days of sorafenib or placebo therapy. (NCT00813293)
Timeframe: Up to day 14 since enrollment
| Intervention | percentage of particpants (Number) |
|---|---|
| Sorafenib | 90 |
| Placebo | 90 |
AEs were assessed based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v3.0). The number of Grade 1-4 AEs with treatment attribution possibly, probably or definitely related up to day 9 of study drug treatment were counted for this outcome. Worst grade by patient within AE type was calculated. Participants could have multiple different AE types within a grade. (NCT00813293)
Timeframe: Day 9
| Intervention | adverse events (Number) |
|---|---|
| Sorafenib | 8 |
| Placebo | 4 |
AEs were assessed based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v3.0). The number of Grade 1-4 AEs with treatment attribution possibly, probably or definitely related on day of RFA treatment were counted for this outcome. Worst grade by patient within AE type was calculated. Participants could have multiple AE types within a grade. (NCT00813293)
Timeframe: Up to day 14 (target day 10 RFA)
| Intervention | adverse events (Number) |
|---|---|
| Sorafenib | 5 |
| Placebo | 4 |
AEs were assessed based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v3.0). The number of Grade 1-4 AEs with treatment attribution possibly, probably or definitely related one month after RFA treatment were counted for this outcome. Worst grade by patient within AE type was calculated. Participants could have multiple AE types within a grade. (NCT00813293)
Timeframe: Up to day 40 post RFA (target 30 days)
| Intervention | adverse events (Number) |
|---|---|
| Sorafenib | 8 |
| Placebo | 4 |
67 reviews available for niacinamide and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Indoles; | 2017 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2017 |
Antiangiogenic therapies for advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Fibroblast Growth Factors; Humans; Liver Neoplas | 2013 |
Endometrial adult/progenitor stem cells: pathogenetic theory and new antiangiogenic approach for endometriosis therapy.
Topics: Adult; Adult Stem Cells; Angiogenesis Inhibitors; Animals; Endometriosis; Endometrium; Female; Human | 2014 |
Development of molecular targeted drugs for advanced thyroid cancer in Japan.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Japan; Molecular Targeted Therapy; Neovascu | 2014 |
Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; | 2015 |
Novel drugs in clinical development for hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Design; Humans; Live | 2015 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; | 2016 |
Antiangiogenic therapy in oncology: current status and future directions.
Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, | 2016 |
New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovascularization, Patho | 2017 |
Sorafenib in lung cancer: clinical developments and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; F | 2008 |
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2008 |
Management of advanced hepatocellular carcinoma in the era of targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma | 2009 |
[Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Controlled Clinical Trials as T | 2009 |
New drugs for the treatment of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; ErbB Receptors; Humans; Mitogen | 2009 |
PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellula | 2009 |
Targeting angiogenesis in bladder cancer.
Topics: Angiogenesis Inhibitors; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2009 |
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2009 |
Renal toxicity of targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical | 2009 |
Angiogenesis regulated by VEGF and its receptors and its clinical application.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2009 |
The role of antiangiogenesis therapy: bevacizumab and beyond.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
[Current advances in molecular targeted therapy of primary hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Adhesion; Cell Proliferati | 2009 |
Molecular targeting for treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovas | 2009 |
Review article: the management of hepatocellular carcinoma.
Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black Pe | 2010 |
Progress in the management of advanced renal cell carcinoma (RCC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
[Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2010 |
[Antiangionic drugs in soft tissue sarcoma].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal | 2010 |
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug D | 2010 |
Angiogenesis as a therapeutic target in urothelial carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzene | 2010 |
Antiangiogenic therapy for breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Breast N | 2010 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Therapeutic advances in women's cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2011 |
[Novelties in the treatment for advanced renal-cell cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2011 |
Targeting angiogenesis in esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2011 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; I | 2011 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical | 2011 |
Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs | 2011 |
Anti-angiogenic therapy: concept to clinic.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; | 2012 |
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Synergism; Endoplasmic Ret | 2011 |
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Chemotaxis; C | 2012 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indole | 2012 |
Sorafenib for treatment of hepatocellular carcinoma: a systematic review.
Topics: Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Chemoemb | 2012 |
Sorafenib in non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; H | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellula | 2012 |
Targeted agents and systemic therapy in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB | 2013 |
[Advances in the study of structural modifications of multi-target anticancer drug sorafenib].
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Molecular Structure; Neoplasms; Neovascula | 2012 |
Raf kinase as a target for anticancer therapeutics.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumo | 2005 |
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Human | 2005 |
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
Topics: Benzenesulfonates; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Neovascularization, Pa | 2005 |
Update on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzene | 2005 |
Sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; | 2006 |
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2007 |
Drug insight: VEGF as a therapeutic target for breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2007 |
Sorafenib: in advanced renal cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Humans; Kidney | 2007 |
Angiogenesis in cancer: molecular mechanisms, clinical impact.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; I | 2007 |
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2007 |
[Effect of angiogenesis inhibitors on renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Human | 2007 |
[Angiogenesis and renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2007 |
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma | 2007 |
[Angiogenesis targeting in renal carcinomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2007 |
[Renal cell carcinoma and antiangiogenic therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2008 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2008 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; C | 2007 |
Hypoxia as a target for combined modality treatments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbon Dioxide; Cell Hypoxia; Combined Modality Ther | 2002 |
7 trials available for niacinamide and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Phar | 2013 |
Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib.
Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chicago; Down-Regulatio | 2016 |
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; B | 2011 |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2011 |
Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Cont | 2012 |
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antin | 2008 |
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; | 2008 |
132 other studies available for niacinamide and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Chemical constituents from the rare mushroom Calvatia nipponica inhibit the promotion of angiogenesis in HUVECs.
Topics: Agaricales; Angiogenesis Inhibitors; Cell Survival; Dose-Response Relationship, Drug; Human Umbilica | 2017 |
Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line, Tumor; Dog Diseases; Dogs; | 2022 |
[Sorafenib regulates vascular endothelial growth factor by runt-related transcription factor-3 to inhibit angiogenesis in hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Core Binding Factor Alpha 3 Subu | 2022 |
Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Calcium-Binding Proteins; Cel | 2020 |
ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Bispecific; Apoptosis; Calcium-Binding Pr | 2020 |
Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Ferric Compounds; Heterografts; Humans; | 2017 |
Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relati | 2017 |
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Stu | 2018 |
[Evaluation of cryptotanshinone inhibition of angiogenesis in human hepatic sinusoidal endothelial cells].
Topics: Animals; Animals, Genetically Modified; Cell Proliferation; Cells, Cultured; Down-Regulation; Drugs, | 2016 |
Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase.
Topics: Animals; Apoptosis; Disease Models, Animal; Disease-Free Survival; Extracellular Signal-Regulated MA | 2013 |
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B | 2013 |
Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma.
Topics: Blood Vessels; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Profiling; Humans; | 2013 |
A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Gene Expr | 2013 |
Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohor | 2013 |
The evolving landscape of therapeutic drug development for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Epigenesis, Genetic; Er | 2013 |
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell | 2013 |
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Line, Tumor; Dise | 2013 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diph | 2013 |
Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; | 2013 |
Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
Topics: Angiogenesis Inhibitors; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western | 2013 |
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.
Topics: Animals; Apoptosis; Benzazepines; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Male; Mi | 2013 |
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antineoplastic Agents; Carcinoma, Hepatocellular; Co | 2013 |
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined C | 2014 |
The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.
Topics: Animals; Common Bile Duct; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Hepatopulmon | 2014 |
SL1122-37, a novel derivative of sorafenib, has greater effects than sorafenib on the inhibition of human hepatocellular carcinoma (HCC) growth and prevention of angiogenesis.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Prol | 2013 |
Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles | 2014 |
Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitab | 2014 |
Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7).
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Carcinoma, E | 2014 |
Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Drug Resistance, Neoplasm; Humans; Inhibitor of Apop | 2014 |
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease-Free Surv | 2014 |
Treatment of collecting duct carcinoma: current status and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cel | 2014 |
Treatment of collecting duct carcinoma: current status and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cel | 2014 |
Treatment of collecting duct carcinoma: current status and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cel | 2014 |
Treatment of collecting duct carcinoma: current status and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cel | 2014 |
Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2014 |
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Trans | 2014 |
A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor | 2014 |
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Anima | 2014 |
Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent.
Topics: Animals; Antineoplastic Agents; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Death; Dos | 2014 |
The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib.
Topics: Acetyltransferases; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular | 2014 |
Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Gene Knockdown Techniques; Humans; Melanoma; Mic | 2014 |
Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Sur | 2014 |
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeo | 2014 |
Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Human | 2015 |
2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Topics: 2-Methoxyestradiol; Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic | 2014 |
The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells.
Topics: Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; DNA Damage; H | 2014 |
Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma.
Topics: Adult; Animals; beta Catenin; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Chil | 2015 |
NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival | 2014 |
Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopharma | 2015 |
Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Disease Mode | 2015 |
Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellul | 2015 |
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma | 2015 |
1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Hep | 2015 |
Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
Topics: Adult; Animals; Apoptosis; Case-Control Studies; Cell Proliferation; Cells, Cultured; Disease Models | 2015 |
Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Topics: Angiogenesis Inhibitors; Animals; Benzylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemoki | 2015 |
Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Calcium-Binding Proteins; Dise | 2015 |
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Di | 2015 |
Murine colitis treated with multitargeted tyrosine kinase inhibitors.
Topics: Animals; Axitinib; Colitis; Imidazoles; Indazoles; Indoles; Male; Mice; Mice, Inbred C57BL; Microves | 2016 |
DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cel | 2016 |
Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling.
Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Bufanolides; Cell Cycle; Cell Movement; Cell Pro | 2016 |
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutati | 2016 |
Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Li | 2016 |
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Actins; Animals; Antigens, CD34; Antineoplastic Agents; Blood Vessels; Carcinoma, Hepatocellular; Co | 2016 |
Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models.
Topics: Antineoplastic Agents; Breast Neoplasms; Computer Graphics; Computer Simulation; Drug Discovery; Gen | 2016 |
Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor | 2017 |
Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model.
Topics: Animals; Catheter Ablation; Cell Line, Tumor; Chemotherapy, Adjuvant; Contrast Media; Diffusion Magn | 2016 |
IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Apoptos | 2016 |
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver | 2016 |
Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2
Topics: Animals; ATP-Binding Cassette Transporters; Cell Death; Cell Line, Tumor; Disease Models, Animal; Dr | 2017 |
Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor | 2017 |
Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Bre | 2008 |
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Wes | 2008 |
Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy.
Topics: Angiopoietin-1; Animals; Apoptosis; Benzenesulfonates; Doxycycline; Endothelial Cells; Enzyme Activa | 2009 |
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Line, Tumor; Cell Prolife | 2009 |
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Fatal Outcome; Female; Hemangiopericytoma; Humans; | 2010 |
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Image Processing, Computer | 2009 |
Tumor endothelial cells join the resistance.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2009 |
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellu | 2009 |
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Comput | 2009 |
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Cell Proliferation; Cytokines; Down-Regulation; | 2009 |
Everolimus: in advanced renal cell carcinoma.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase III as Topic; D | 2009 |
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellu | 2010 |
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Division; Cell Line, Tumor; Cytos | 2009 |
Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
Topics: Adrenal Gland Neoplasms; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; | 2010 |
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Topics: Animals; Antigens, Bacterial; Bacterial Toxins; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Cell | 2010 |
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; | 2010 |
Sorafenib exerts anti-glioma activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Brain Neoplasms; Cell Line, | 2010 |
Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Combined Chemothera | 2010 |
Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Disease | 2010 |
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Lin | 2010 |
Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media.
Topics: Analysis of Variance; Animals; Area Under Curve; Benzenesulfonates; Blood-Brain Barrier; Brain Neopl | 2010 |
Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2012 |
Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship | 2011 |
Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; | 2011 |
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-C | 2011 |
Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2011 |
An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Growth Processes; Cell Li | 2011 |
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relati | 2011 |
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; B | 2011 |
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; | 2011 |
BRN-103, a novel nicotinamide derivative, inhibits VEGF-induced angiogenesis and proliferation in human umbilical vein endothelial cells.
Topics: Angiogenesis Inhibitors; Cells, Cultured; Endothelium, Vascular; Humans; Neovascularization, Patholo | 2011 |
AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatoce | 2011 |
Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Cycle; Cell Line, T | 2012 |
Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; | 2012 |
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinom | 2012 |
RAIN-Droplet: a novel 3D in vitro angiogenesis model.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cells, C | 2012 |
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Benzene | 2012 |
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug | 2012 |
Contrast-enhanced ultrasonography for evaluating antiangiogenic treatment in hepatocellular carcinoma. A long way from research to clinical practice.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Neovascularizat | 2012 |
The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hep | 2012 |
Molecular mechanisms of sorafenib action in liver cancer cells.
Topics: Apoptosis; Benzenesulfonates; Biological Transport; Carcinoma, Hepatocellular; Cell Adhesion; Cell C | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Carcinoma, Hepatocellular; Clinical Trials, Phase I | 2012 |
Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
Topics: Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Contrast Media; Disease Models, Animal; Huma | 2013 |
Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulat | 2012 |
Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis.
Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Cell Movement; Cell Proliferation; Cells, Culture | 2012 |
The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamin | 2013 |
Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
Topics: Animals; Antineoplastic Agents; Catheter Ablation; Combined Modality Therapy; Disease Progression; H | 2013 |
Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; | 2013 |
How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.
Topics: Adenoma, Islet Cell; Animals; Antigens, Polyomavirus Transforming; Apoptosis; Disease Progression; F | 2012 |
Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.
Topics: Aneuploidy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; | 2013 |
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Hum | 2004 |
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Hum | 2004 |
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Hum | 2004 |
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Hum | 2004 |
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Topics: Animals; Apoptosis; Benzenesulfonates; Cell Growth Processes; Cell Line, Tumor; Humans; MAP Kinase S | 2005 |
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferat | 2006 |
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Death | 2006 |
Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Neovascularization, Pathologic; Niacina | 2007 |
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Movement; Cell Prol | 2007 |
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.
Topics: Analysis of Variance; Animals; Benzenesulfonates; Carcinoma, Renal Cell; Catheter Ablation; Combined | 2007 |
The ability of nicotinamide to inhibit the growth of a C3H mouse mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Division; Cyclohexanes; Dose-Response Relationship, Drug; Fatty | 1995 |
Use of thymidine analogues to indicate vascular perfusion in tumours.
Topics: Animals; Blood Flow Velocity; Female; Flow Cytometry; Hydralazine; Idoxuridine; Image Processing, Co | 2000 |
Chemical identification of a tumor-derived angiogenic factor.
Topics: Angiogenesis Inducing Agents; Animals; Carcinoma 256, Walker; Cells, Cultured; Chick Embryo; Cornea; | 1987 |
Nicotinamide enhances skin flap survival.
Topics: Animals; Dose-Response Relationship, Drug; Graft Survival; Male; Neovascularization, Pathologic; Nia | 1989 |